Images List Premium Download Classic

Isoquinolin

Isoquinolin-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
Corneal thickness adjustment agent
Kowa Company, Ltd.
October 12, 2017 - N°20170290840

The present invention provides a novel corneal thickness modulating agent. The present invention pertains to a corneal thickness modulating agent containing 1-(4-fluoro-5-isoquinolinesulfonyl)-2-methyl-1,4-homopiperazine or a salt thereof or a solvate thereof.
Tetrahydroisoquinoline derived prmt5-inhibitors
Ctxt Pty Ltd
October 05, 2017 - N°20170283407

A compound of formula (i) wherein: r1 is optionally one or more halo or methyl groups; r2a and r2b are independently selected from the group consisting of: (i) f; (ii) h; (iii) me; and (iv) ch2oh; r2c and r2d are independently selected from the group consisting of: (i) f; (ii) h; (iii) me; and (iv) ...
Combination therapy
Aerie Pharmaceuticals, Inc.
October 05, 2017 - N°20170281613

Described herein are compounds and compositions for treating glaucoma and/or reducing introcular pressure. Compositions may comprise an isoquinoline compound and a prostaglandin or a prostaglandin analog. Compounds described herein include those in which an isoquinoline compound is covalently linked to a prostaglandin or a prostaglandin analog, and those in which an isoquinoline compound and a prostaglandin free acid together ...
Isoquinolin Patent Pack
Download + patent application PDFs
Isoquinolin Patent Applications
Download + Isoquinolin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Isoquinolin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
Merck Sharp & Dohme Corp.
September 28, 2017 - N°20170273966

The present invention relates to a compound represented by formula i:and pharmaceutically acceptable salts thereof. The compounds of formula i are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2. The compounds of the present invention may be useful in the treatment of hepatic ...
Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2
Merck Sharp & Dohme Corp.
September 28, 2017 - N°20170273965

The present invention relates to a compound represented by formula (i): and pharmaceutically acceptable salts thereof. The compounds of formula (i) are inhibitors of diacylglyceride o-acyltransferase 2 (“dgat2”) and may be useful in the treatment, prevention and suppression of diseases mediated by dgat2. The compounds of the present invention may be useful in the treatment of hepatic ...
Drug combination
Verona Pharma Plc
September 21, 2017 - N°20170266190

The invention provides a composition which comprises (a) a pde3/pde4 inhibitor which is 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a muscarinic receptor antagonist.
Isoquinolin Patent Pack
Download + patent application PDFs
Isoquinolin Patent Applications
Download + Isoquinolin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Isoquinolin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Bi-benzyl isoquinoline derivative, preparation method and use thereof in hepatopathy treatment and prevention
Versitech Ltd.
September 14, 2017 - N°20170260161

The invention disclosed a compound of general formula (i), a single stereoisomer thereof, a mixture of stereoisomers thereof, and a prodrug, pharmaceutically acceptable salt and metabolite thereof, x1, x2, x3, x4, r1, r2, x, y and z being as defined in the present invention.
Noscapinoid-producing microbes and methods of making and using the same
The Board Of Trustees Of The Leland Stanford Junior University
September 07, 2017 - N°20170253898

Engineered non-plant cells that produce a benzylisoquinoline alkaloid product that is a derivative of canadine along a metabolic pathway that converts canadine, or an analog of canadine, to a noscapinoid product are provided. Methods of culturing engineered non-plant cells that produce a noscapinoid product and pharmaceutical compositions are also provided.
Isoquinolinone derivatives useful in the treatment of cancer
Pierre Fabre Medicament
August 24, 2017 - N°20170240544

The present invention relates to a compound of the following formula (i) or a pharmaceutically acceptable salt and/or solvate thereof, notably for use as a drug, notably in the treatment of cancer, as well as pharmaceutical compositions containing such a compound and processes to prepare such a compound.
Liquid inhalation formulation comprising rpl554
Verona Pharma Plc
August 24, 2017 - N°20170239178

The present invention relates to a liquid pharmaceutical composition suitable for administration by inhalation which comprises a diluent and a suspension of particles of 9,10-dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(n-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2h-pyrimido[6,1-a]isoquinolin-4-one (rpl554) or a pharmaceutically acceptable salt thereof. Also described is a liquid pharmaceutical composition according to the invention for use in the treatment ...
Tetrahydroisoquinoline derivatives
Cytokinetics, Incorporated
August 17, 2017 - N°20170233402

Novel tetrahydroisoquinoline derivative compounds are disclosed herein that may be used as an active ingredient for a pharmaceutical composition, and in particular, for a pharmaceutical composition useful for preventing or treating a disease or condition responsive to modulation of the contractility of the skeletal sarcomere. This may be accomplished, for example, by modulation of the troponin complex of the fast ...
1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as ...
Eli Lilly And Company
August 17, 2017 - N°20170233378

1-oxo-1,2-dihydroisoquinolin-7-yl-(5-substituted-thiophen-2-yl)-sulfonamide compounds, formulations containing those compounds, and their use as aicarft inhibitors.
Combined use of an alpha-adrenergic receptor antagonist and an anti-muscarinic agent
Astellas Ireland Co., Ltd.
August 17, 2017 - N°20170231974

The combined use of (r)-5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzene-1-sulfonamide (tamsulosin), or its pharmaceutically acceptable salt, and (1s)-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylic acid (3r)-quinuclidin-3-yl ester (solifenacin), or its pharmaceutically acceptable salt, for the preparation of a medicament for the improvement of lower urinary tract symptoms associated with benign prostatic hyperplasia (luts/bph) ...
Isoquinolin Patent Pack
Download + patent application PDFs
Isoquinolin Patent Applications
Download + Isoquinolin-related PDFs
For professional research & prior art discovery
inventor
  • + full patent PDF documents of Isoquinolin-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Redoxindicators
Roche Diagnostics Operations, Inc.
July 06, 2017 - N°20170191990

The present invention relates to a chemical compound or a salt or solvate thereof being a phenazine-, phenanthridine-, phenanthroline-, quinoline-, quinoxaline-, acridine- isoquinoline-, pyrazine- or pyridine-derivative comprising a conjugated π-system and a π-acceptor group, and to uses thereof. The present invention further relates to a chemistry matrix and to a test element comprising the chemical compound ...
Crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2...
Glaxosmithkline Intellectual Property Development Limited
July 06, 2017 - N°20170190688

Disclosed are novel crystalline salts of (s)-6-((1-acetylpiperidin-4-yl)amino)-n-(3-(3,4-dihydroisoquinolin-2(1h)-yl)-2-hydroxypropyl)pyrimidine-4-carboxamide and pharmaceutical compositions containing the same. Also disclosed are processes for the preparation thereof and methods for use thereof.
Crystalline forms of a prolyl hydroxylase inhibitor
Fibrogen, Inc.
July 06, 2017 - N°20170190667

The present disclosure relates to crystalline solid forms of [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid, the process of preparing the forms, and pharmaceutical compositions and methods of use thereof.
Tetrahydroisoquinolin-1-one derivative or salt thereof
Seldar Pharma Inc.
July 06, 2017 - N°20170189390

To provide a pharmaceutical, in particular a compound which can be used as a therapeutic agent for irritable bowel syndrome (ibs). It was found that a tetrahydroisoquinolin-1-one derivative having an amide group at the 4-position or a pharmaceutically acceptable salt thereof has an excellent bombesin 2 (bb2) receptor antagonistic action. It is also found that the tetrahydroisoquinolin-1-one derivative is ...
Biisoquinoline compounds and methods of treatment
University Of Florida Research Foundation
June 29, 2017 - N°20170183349

The instant invention describes biisoquinoline compounds having therapeutic activity, and methods of treating dis-orders such as cancer, tumors and cell proliferation related disorders, or affect cell differentiation, dedifferentiation or transdifferentiation.
Synthetic methods for preparation of (s)-(2r,3r,11br)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1...
Neurocrine Biosciences, Inc.
June 29, 2017 - N°20170183346

Provided herein are processes for the preparation of (s)-(2r,3r,11br-3-isobuty-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1h-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate), or a solvate, hydrate, or polymorph thereof.
Cocrystal, production method thereof, and medicament containing cocrystal
Takeda Pharmaceutical Company Limited
June 29, 2017 - N°20170183326

The present invention provides a cocrystal of (s)-3-(1-((1-acryloylpyrrolidin-3-yl)oxy)isoquinolin-3-yl)-1h-1,2,4-triazol-5(4h)-one and an organic acid capable of forming a cocrystal with the compound.
Polymerizable liquid crystal compound, composition, liquid crystal polymerization film-kind thereof and use thereof
Takeda Pharmaceutical Company Limited
June 22, 2017 - N°20170174992

In which, in formula (1), g is a group composed of a quinoline skeleton, an isoquinoline skeleton, a quinoxaline skeleton or a quinazoline skeleton, a1 is 1,4-phenylene or 1,4-cyclohexylene, z1 is a connecting group, m is an integer from 0 to 3, and r1 is a group containing a polymerizable group.
Loading